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Background 
Millions of children worldwide acquire HIV/AIDS as a 
result of mother-to-child transmission during pregnancy 
or breastfeeding. A course of antiretroviral drugs given 
to pregnant women and their newborn babies could 
reduce the risk of mother to child transmission  
Inclusion criteria 
Studies:  
Randomized controlled trials. 
Participants: 
Pregnant women with HIV, or infants born to mothers 
with HIV. 
Intervention: 
Any antiretroviral (ARV) regimen aiming to decrease the 
risk of mother-to-child transmission of HIV.  
Outcomes: 
In the baby: HIV infection status up to 18 months, death, 
severe adverse events. 
In the mother: severe adverse events. 
Results 
• Eighteen trials involving 14,398 women were 
included; 11 trials were adequately concealed. 
• Six trials compared zidovudine (ZDV), alone or with 
lamivudine (3TC) with placebo. Taken in the antenatal 
period and during labour, fewer babies in the ZDV 
groups had HIV infection. Efficacy ranged from 10% 
to 66%. 
• Four trials compared longer and shorter regimens of 
the same drugs. In one trial, ZDV for mothers from 28 
weeks of pregnancy, during labour, and for babies for 
three days reduced HIV infection at six months 
(efficacy 45%), compared with ZDV for mothers from 
35 weeks, during labour and for babies for six weeks. 
There were no significant differences detected for 
other comparisons. 
• Eight trials compared different drugs with ZDV, either 
alone or in combination. One trial compared single 
dose nevirapine (NVP) for mothers in labour, plus a 
single dose for babies immediately after birth versus 
single dose ZDV in labour and for babies for one 
week after birth; fewer babies in the NVP group had 
HIV infection at 18 months (efficacy 39%). There were 
no significant differences detected in trials of other 
comparisons. 
• No severe adverse events were found in any trial. 
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Does giving pregnant women or their newborn babies a short course of 
antiretroviral drugs reduce HIV transmission to the baby?  
Both short and longer regimens of antiretroviral treatments reduce 
transmission of HIV from mothers to babies. 
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Authors’ conclusions 
Implications for practice:  
Short ARV treatment courses reduce the transmission of HIV from mothers to their babies. A range of ARV regimens 
appear effective: these include regimens started antenatally, and those given immediately after birth. It is not yet 
clear which regimen is best.  
Implications for research: 
Further large, well designed trials are needed to identify treatment regimens that minimize the likelihood of 
resistance emerging, as are studies assessing long-term safety of ARV drugs in mothers and babies. 
Longer vs shorter ARV regimens: HIV infection at 6 months 
 
 
Antiretrovirals vs placebo: HIV infection at 4 to 8 weeks 
